We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient.
- Authors
Pestchanker, Claudia; Diaconchuk, Melina; Lopez, Paula; Montaño, María Rosa; Romero, William; Zalazar, Guillermo; Carnero Contentti, Edgar
- Abstract
Background: Recently, satralizumab (interleukin-6 receptor blocker) was approved for seropositive neuromyelitis optica spectrum disorder (NMOSD) patients. In SAkuraSky trial, mild neutropenia was reported in 15% of patients under satralizumab. Most neutropenias were transient; grade 3–4 was not related to serious infections. So far, no severe neutropenia (<100 cell/mm3) has been reported worldwide. Methods: We present an aquaporin-4-antibody-positive NMOSD patient who developed severe febrile neutropenia 2 weeks after adding satralizumab to her azathioprine treatment. Conclusion: Analytic control for satralizumab is recommended at 4 weeks. However, we recommend this control at week 2, in order to closely monitor neutrophil count and prevent further complications.
- Subjects
FEBRILE neutropenia; NEUROMYELITIS optica; INTERLEUKIN-6 receptors
- Publication
Multiple Sclerosis Journal, 2023, Vol 29, Issue 1, p150
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/13524585221137231